公开(公告)号：AU2020330570A1

公开(公告)日：2022-03-17

申请号：AU2020330570

申请日：2020-08-13

Applicant: VERTEX PHARMA

Inventor： ANGELL PAUL ,  COCHRAN JOHN E ,  LITTLER BENJAMIN J ,  SIESEL DAVID ANDREW ,  URBINA ARMANDO ,  ANDERSON COREY DON ,  CLEMENS JEREMY J ,  CLEVELAND THOMAS ,  COON TIMOTHY RICHARD ,  FRIEMAN BRYAN ,  HADIDA RUAH SARA SABINA ,  MCCARTNEY JASON ,  MILLER MARK THOMAS ,  PARASELLI PRASUNA ,  PIERRE FABRICE ,  SWIFT SARA E ,  ZHOU JINGLAN

IPC: C07D207/08 ,  C07D207/09 ,  C07D213/61 ,  C07D213/62 ,  C07D213/70 ,  C07D213/74 ,  C07D231/20 ,  C07D401/04 ,  C07D401/14 ,  C07D513/22

Abstract: The disclosure provides processes for synthesizing Compound I, and pharmaceutically acceptable salts thereof.

公开(公告)号：UY38837A

公开(公告)日：2021-02-26

申请号：UY38837

申请日：2020-08-13

Applicant: VERTEX PHARMA

Inventor： CLEMENS JEREMY J ,  ANDERSON COREY DON ,  CLEVELAND THOMAS ,  COON TIMOTHY RICHARD ,  FRIEMAN BRYAN ,  HADIDA RUAH SARA SABINA ,  MCCARTNEY JASON ,  MILLER MARK THOMAS ,  PARASELLI PRASUNA ,  PIERRE FABRICE ,  SWIFT SARA E ,  ZHOU JINGLAN ,  ANGELL PAUL ,  COCHRAN JOHN E ,  LITTLER BENJAMIN J ,  SIESEL DAVID ANDREW ,  URBINA ARMANDO ,  GROOTENHUIS PETER

IPC: A61P11/00 ,  C07D207/08 ,  C07D213/71 ,  C07D213/82 ,  C07D231/20 ,  C07D401/04 ,  C07D401/14 ,  C07D513/22

Abstract: La descripción proporciona procesos para sintetizar el Compuesto I, y sus sales farmacéuticamente aceptables.

公开(公告)号：PL2940017T3

公开(公告)日：2020-03-31

申请号：PL15151822

申请日：2012-09-28

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  STUDLEY JOHN ,  PIERARD FRANCOISE YVONNE THEODORA MARIE ,  DURRANT STEVEN JOHN ,  LITTLER BENJAMIN JOSEPH ,  HUGHES ROBERT MICHAEL ,  SIESEL DAVID ANDREW ,  ANGELL PAUL ,  URBINA ARMANDO ,  SHI YI

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00

公开(公告)号：AU2019210688A1

公开(公告)日：2019-08-22

申请号：AU2019210688

申请日：2019-08-05

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  STUDLEY JOHN ,  PIERARD FRANCOISE YVONNE THEODORA MARIE ,  DURRANT STEVEN JOHN ,  LITTLER BENJAMIN JOSEPH ,  HUGHES ROBERT MICHAEL ,  SIESEL DAVID ANDREW ,  ANGELL PAUL ,  URBINA ARMANDO ,  SHI YI

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00

Abstract: Abstract The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I or II: NH2 0.- N 2 ~ R9bR1 N _LH R R4 R3a NH2 R R 3c Ric R4 Rib wherein the variables are as defined herein.

公开(公告)号：NZ719122A

公开(公告)日：2017-12-22

申请号：NZ71912212

申请日：2012-09-28

Applicant: VERTEX PHARMA

Inventor： DURRANT STEVEN JOHN ,  CHARRIER JEAN-DAMIEN ,  STUDLEY JOHN ,  PIERARD FRANCOISE YVONNE THEODORA MARIE ,  LITTLER BENJAMIN JOSEPH ,  HUGHES ROBERT MICHAEL ,  SIESEL DAVID ANDREW ,  URBINA ARMANDO ,  SHI YI ,  ANGELL PAUL

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00

Abstract: The present disclosure relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present disclosure also relates to compounds useful as inhibitors of ATR protein kinase. The disclosure relates to pharmaceutically acceptable compositions comprising the compounds; methods of treating of various diseases, disorders, and conditions using the compounds; processes for preparing the compounds; intermediates for the preparation of the compounds; and solid forms of the compounds. The compounds have formula (I) or (II) wherein the variables are as defined herein.

公开(公告)号：AU2017206213A1

公开(公告)日：2017-08-03

申请号：AU2017206213

申请日：2017-07-20

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  STUDLEY JOHN ,  PIERARD FRANCOISE YVONNE THEODORA MARIE ,  DURRANT STEVEN JOHN ,  LITTLER BENJAMIN JOSEPH ,  HUGHES ROBERT MICHAEL ,  SIESEL DAVID ANDREW ,  ANGELL PAUL ,  URBINA ARMANDO ,  SHI YI

IPC: C07D413/04 ,  A61K31/497 ,  A61P35/00

Abstract: Abstract [002821 The present invention relates to processes and intermediates for preparing compounds useful as inhibitors of ATR kinase, such as aminopyrazine-isoxazole derivatives and related molecules. The present invention also relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. [002831 The compounds of this invention have formula I or II: NH 0 -N HN R NH 2 04 H -R4 R N- Rla RC R4 R lb wherein the variables are as defined herein.

公开(公告)号：IN943KON2014A

公开(公告)日：2015-08-21

申请号：IN943KON2014

申请日：2014-04-30

Applicant: VERTEX PHARMA

Inventor： CHARRIER JEAN-DAMIEN ,  STORCK PIERRE-HENRI ,  STUDLEY JOHN ,  PIERARD FRANCOISE YVONNE THEODORA MARIE ,  DURRANT STEVEN JOHN ,  LITTLER BENJAMIN JOSEPH ,  ANGELL PAUL ,  HUGHES ROBERT MICHAEL ,  SIESEL DAVID ANDREW ,  URBINA ARMANDO ,  ZWICKER CARL ,  LOCONTE NICHOLAS ,  BARDER TIMOTHY

IPC: C07D413/14 ,  A61K31/497 ,  A61P35/00

Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I-1: wherein the variables are as defined herein. Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.

公开(公告)号：MX2014003796A

公开(公告)日：2015-01-16

申请号：MX2014003796

申请日：2012-09-28

Applicant: VERTEX PHARMA

Inventor： STORCK PIERRE-HENRI ,  DURRANT STEVEN JOHN ,  CHARRIER JEAN-DAMIEN ,  STUDLEY JOHN ,  PIERARD FRANCOISE YVONNE THEODORA MARIE ,  LITTLER BENJAMIN JOSEPH ,  HUGHES ROBERT MICHAEL ,  SIESEL DAVID ANDREW ,  ANGELL PAUL ,  URBINA ARMANDO ,  ZWICKER CARL ,  LOCONTE NICHOLAS ,  BARDER TIMOTHY

IPC: C07D413/14 ,  A61K31/497 ,  A61P35/00

Abstract: La presente invención se refiere a compuestos útiles como inhibidores de la proteína cinasa ATR. La invención se refiere, además, a composiciones farmacéuticamente aceptables que comprenden los compuestos de esta invención; métodos para tratar diversas enfermedades, trastornos y condiciones con el uso de los compuestos de esta invención, procesos para preparar los compuestos de esta invención, intermedios para preparar los compuestos de esta invención, formas sólidas de los compuestos de esta invención, y métodos de uso de los compuestos en aplicaciones in vitro tales como el estudio de cinasas en fenómenos biológicos y patológicos, el estudio de las vías de transducción de señales intracelulares mediadas por esas cinasas, y la evaluación comparativa de nuevos inhibidores de cinasas. Los compuestos de esta invención tienen la fórmula I-1: (ver formula) en donde las variables son tal como se definan en la presente descripción. Además, los compuestos de esta invención tienen la formula II: (ver formula II) O una sal farmacéuticamente aceptable de estos, en donde las variables son como se definen en la presente descripción.